Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

被引：21

作者：

Wensink, G. Emerens ^{[1
]}

Elferink, Marloes A. G. ^{[2
]}

May, Anne M. ^{[3
]}

Mol, Linda ^{[2
]}

Hamers, Patricia A. H. ^{[1
]}

Bakker, Sandra D. ^{[4
]}

Creemers, Geert-Jan ^{[5
]}

de Groot, Jan Willem B. ^{[6
]}

de Klerk, Gerty J. ^{[7
]}

Haberkorn, Brigitte C. M. ^{[8
]}

Haringhuizen, Annebeth W. ^{[9
]}

Hoekstra, Ronald ^{[10
]}

Hunting, J. Cornelis B. ^{[11
]}

Kerver, Emile D. ^{[12
]}

Mathijssen-van Stein, Danielle ^{[13
]}

Polee, Marco B. ^{[14
]}

Pruijt, Johannes F. M. ^{[15
]}

Quarles van Ufford-Mannesse, Patricia ^{[16
]}

Radema, Sandra ^{[17
]}

Rietbroek, Ronald C. ^{[18
]}

Simkens, Lieke H. J. ^{[19
]}

Tanis, Bea C. ^{[20
]}

ten Bokkel Huinink, Daan ^{[21
]}

Tjin-A-Ton, Manuel L. R. ^{[22
]}

Tromp-van Driel, Cathrien S. ^{[23
]}

Troost, Monique M. ^{[24
]}

van de Wouw, Agnes J. ^{[25
]}

van den Berkmortel, Franchette W. P. J. ^{[26
]}

van der Pas, Anke J. M. ^{[27
]}

van der Velden, Ankie M. T. ^{[28
]}

van Dijk, Marjan A. ^{[29
]}

van Dodewaard-de Jong, Joyce M. ^{[30
]}

van Druten, Edith B. ^{[31
]}

van Voorthuizen, Theo ^{[32
]}

Jan Veldhuis, Gerrit ^{[33
]}

Verheul, Henk M. W. ^{[34
]}

Vestjens, Hanneke J. H. M. J. ^{[25
]}

Vincent, Jeroen ^{[35
]}

Kranenburg, Onno W. ^{[36
,37
]}

Punt, Cornelis J. A. ^{[38
]}

Vink, Geraldine R. ^{[1
,2
]}

Roodhart, Jeanine M. L. ^{[1
]}

Koopman, Miriam ^{[1
]}

机构：

[1] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands

[2] Netherlands Comprehens Canc Org, Dept Res, Postbus 19079, NL-3501 DB Utrecht, Netherlands

[3] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands

[4] Zaans Med Ctr, Dept Med Onco, Postbus 210, NL-1500 EE Zaandam, Netherlands

[5] Catharina Hosp, Dept Med Oncol, Postbus 1350, NL-5602 ZA Eindhoven, Netherlands

[6] Isala Hosp, Dept Med Oncol, Dokter Heesweg 2, NL-8025 AB Zwolle, Netherlands

[7] Spaarne Gasthuis, Dept Med Oncol, Spaarnepoort 1, NL-2134 TM Hoofddorp, Netherlands

[8] Maasstad Hosp, Dept Med Oncol, Postbus 9100, NL-3007 AC Rotterdam, Netherlands

[9] Hosp Gelderse Vallei, Dept Med Oncol, Willy Brandtlaan 10, NL-6716 RP Ede, Netherlands

[10] Ziekenhuisgroep Twente, Dept Med Oncol, Postbus 7600, NL-7600 SZ Almelo, Netherlands

[11] Antonius Hosp, Dept Med Oncol, Postbus 2500, NL-3430 EM Nieuwegein, Netherlands

[12] OLVG, Dept Med Oncol, Oosterpark 9, NL-1091 AC Amsterdam, Netherlands

[13] Franciscus Gasthuis & Vlietland, Dept Med Oncol, Vlietlandpl, NL-3118 JH Schiedam, Netherlands

[14] Med Ctr Leeuwarden, Dept Med Oncol, Postbus 888, NL-8901 BR Leeuwarden, Netherlands

[15] Jeroen Bosch Hosp, Dept Med Oncol, Postbus 90153, NL-5200 ME Shertogenbosch, Netherlands

[16] HagaZiekenhuis, Dept Med Oncol, Els Borst Eilerspl 275, NL-2545 AA The Hague, Netherlands

[17] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Postbus 9101, NL-6500 HB Nijmegen, Netherlands

[18] Rode Kruis Hosp, Dept Med Oncol, Postbus 1074, NL-1940 EB Beverwijk, Netherlands

[19] Maxima Med Ctr, Dept Med Oncol, Postbus 90052, NL-5600 PD Eindhoven, Netherlands

[20] Groene Hart Hosp, Dept Med Oncol, Bleulandweg 10, NL-2803 HH Gouda, Netherlands

[21] Diakonessenhuis Utrecht, Dept Med Oncol, Postbus 80250, NL-3508 TG Utrecht, Netherlands

[22] Hosp Rivierenland, Dept Med Oncol, President Kennedylaan 1, NL-4002 WP Tiel, Netherlands

[23] Gelre Hosp, Dept Med Oncol, Postbus 9014, NL-7300 DS Apeldoorn, Netherlands

[24] Bravis Hosp Bergen Zoom, Dept Med Oncol, Postbus 999, NL-4700 AZ Roosendaal, Netherlands

[25] VieCuri Med Ctr, Dept Med Oncol, Postbus 1926, NL-5900 BX Venlo, Netherlands

[26] Zuyderland Med Ctr Heerlen, Dept Med Oncol, Postbus 5500, NL-6130 MB Geleen, Netherlands

[27] LangeLand Hosp, Dept Med Oncol, Postbus 3015, NL-2700 KJ Zoetermeer, Netherlands

[28] Tergooi, Dept Med Oncol, Riebeeckweg 212, NL-1213 XZ Hilversum, Netherlands

[29] ZorgSaam Hosp, Dept Med Oncol, Wielingenlaan 2, NL-4535 PA Terneuzen, Netherlands

[30] Meander Med Ctr, Dept Med Oncol, Postbus 1502, NL-3800 BM Amersfoort, Netherlands

[31] Reinier Graaf Gasthuis, Dept Med Oncol, Postbus 5011, NL-2600 GA Delft, Netherlands

[32] Hosp Rijnstate, Dept Med Oncol, Wagnerlaan 55, NL-6815 AD Arnhem, Netherlands

[33] Antonius Hosp Sneek, Dept Med Oncol, Postbus 20000, NL-8600 BA Sneek, Netherlands

[34] Univ Amsterdam, Med Ctr, Dept Med Oncol, Box 7057, NL-1007 MB Amsterdam, Netherlands

[35] Elkerliek Hosp, Dept Med Oncol, Postbus 98, NL-5700 AB Helmond, Netherlands

[36] Univ Utrecht, Univ Med Ctr Utrecht, Dept Surg Oncol, Postbus 98, NL-5700 AB Utrecht, Netherlands

[37] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht Platform Organoid Technol, Postbus 98, NL-5700 AB Utrecht, Netherlands

[38] Univ Amsterdam, Med Centers, Dept Med Oncol, Postbus 22660, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2021年 / 124卷 / 02期

关键词：

MICROSATELLITE INSTABILITY; POOLED ANALYSIS; BRAF MUTATION; PHASE-III; CAPECITABINE; OXALIPLATIN; MULTICENTER; BEVACIZUMAB; NIVOLUMAB; PROGNOSIS;

D O I：

10.1038/s41416-020-01076-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. Methods Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials;n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. Results Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. Conclusion Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.

引用

页码：399 / 406

页数：8

共 50 条

[41] ASO Visual Abstract: Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
Koen Zwart
Frederieke H. van der Baan
Cornelis J. A. Punt
G. Emerens Wensink
Karen Bolhuis
Miangela M. Laclé
Wilhelmina M. U. van Grevenstein
Jeroen Hagendoorn
Ignace H. de Hingh
Miriam Koopman
Geraldine Vink
Jeanine Roodhart
Annals of Surgical Oncology, 2023, 30 : 6773 - 6774
[42] Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review
Chakrabarti, Sakti
Grewal, Udhayvir Singh
Vora, Kruti Bhagirath
Parikh, Aparna Raj
Almader-Douglas, Diana
Mahipal, Amit
Sonbol, Mohamad B.
JCO PRECISION ONCOLOGY, 2023, 7
[43] Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients
Aparicio, Thomas
Schischmanoff, Olivier
Poupardin, Cecile
Soufir, Nadem
Angelakov, Celine
Barrat, Christophe
Levy, Vincent
Choudat, Laurence
Cucherousset, Joel
Boubaya, Marouane
Lagorce, Christine
Des Guetz, Gaetan
Wind, Philippe
Benamouzig, Robert
DIGESTIVE AND LIVER DISEASE, 2013, 45 (03) : 245 - 250
[44] Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency
Cohen, Romain
Pellat, Anna
Boussion, Helene
Svrcek, Magali
Lopez-Trabada, Daniel
Trouilloud, Isabelle
Afchain, Pauline
Andre, Thierry
BULLETIN DU CANCER, 2019, 106 (02) : 137 - 142
[45] Outcome of mismatch repair deficient metastatic colorectal cancer (CRC): The Mayo Clinic Experience.
Jin, Zhaohui
Sanhueza, Cristobal T.
Johnson, Benny
Smyrk, Thomas C.
Larson, David W.
Nagorney, David M.
Hubbard, Joleen Marie
Grothey, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Real-world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer
Loft, Matthew
Wong, Vanessa
Kosmider, Suzanne
Wong, Rachel
Shapiro, Jeremy
Hong, Wei
Jennens, Ross
Tie, Jeanne
Caird, Susan
Steel, Simone
Lee, Belinda
Nott, Louise
Khattak, Muhammad Adnan
Lim, Stephanie
Chong, Geoffrey
Hayes, Theresa
Underhill, Craig
Mclachlan, Sue-Anne
Rainey, Natalie
Dunn, Catherine
Gibbs, Peter
INTERNAL MEDICINE JOURNAL, 2025, 55 (01) : 41 - 46
[47] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).
Leal, Alexis Diane
Paludo, Jonas
Finnes, Heidi D.
Grothey, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[48] Deficient Mismatch Repair and BRAF Mutations in Metastatic Colorectal Cancer in the South Island of New Zealand
Yap, Jeremy
Pattison, Sharon
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2025,
[49] "Matching" the "Mismatch" Repair-Deficient Prostate Cancer with Immunotherapy
Schweizer, Michael T.
Yu, Evan Y.
CLINICAL CANCER RESEARCH, 2020, 26 (05) : 981 - 983
[50] Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study
Cheng, Yi-Kan
Chen, Dong-Wen
Chen, Ping
He, Xiaosheng
Li, Pei-Si
Lin, Zhen-Sen
Chen, Shao-Xia
Ye, Shu-Biao
Lan, Ping
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →